Project Details
| Status | Active |
|---|---|
| Effective start/end date | 6/12/22 → 5/12/27 |
A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASKG315 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
- Day, Daphne (Primary Chief Investigator (PCI))
Project: Research